{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:47:41Z","timestamp":1791935261903,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.10.002","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:33:17Z","timestamp":1791318797000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study"],"prefix":"10.1016","author":[{"given":"Stephen L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-3620","authenticated-orcid":false,"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-9332","authenticated-orcid":false,"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Thomas","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-0870","authenticated-orcid":false,"given":"Donatella","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Gerolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Burgoyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert John","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-2682","authenticated-orcid":false,"given":"Jens U.","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugochinyere","family":"Emeribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1877-8666","authenticated-orcid":false,"given":"Boris","family":"Baur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.10.002_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.10.002_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.10.002_bib3","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.10.002_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.10.002_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.10.002_bib6","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.10.002_bib7","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cam4.3116","article-title":"Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab","volume":"9","author":"Fung","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2026.10.002_bib8","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1111\/liv.15130","article-title":"Treatment and the prognosis of hepatocellular carcinoma in Asia","volume":"42","author":"Torimura","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.10.002_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.10.002_bib10","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/cancers17111814","article-title":"Real-world experiences using atezolizumab + bevacizumab for the treatment of unresectable hepatocellular carcinoma: a multicenter study","volume":"17","author":"Abdelrahim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.10.002_bib11","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.10.002_bib12","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3390\/cancers12071968","article-title":"Effectiveness and safety of nivolumab in Child\u2013Pugh B patients with hepatocellular carcinoma: a real-world cohort study","volume":"12","author":"Choi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Suppl 4","key":"10.1016\/j.jhep.2026.10.002_bib13","article-title":"Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases","volume":"43","author":"Chauhan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.10.002_bib14","first-page":"655","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.10.002_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.10.002_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2025.43.4_suppl.587","article-title":"A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child\u2013Pugh class B cirrhosis: CHALLENGE trial final results","volume":"43","author":"Ikeda","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.10.002_bib17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.10.002_bib18","doi-asserted-by":"crossref","first-page":"S832","DOI":"10.1016\/j.annonc.2025.08.2124","article-title":"Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants with unresectable hepatocellular carcinoma from the combined China extension and global cohorts in the Phase 3 HIMALAYA study","volume":"36","author":"Sangro","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.10.002_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"Rimassa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.10.002_bib20","doi-asserted-by":"crossref","DOI":"10.1159\/000549955","article-title":"Early safety results from the phase 3b SIERRA study of durvalumab and tremelimumab as first-line treatment for participants with unresectable hepatocellular carcinoma and a poor prognosis","author":"Chan","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.10.002_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.10.002_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.10.002_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/HEP.0000000000001385","article-title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial","volume":"83","author":"Lau","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.10.002_bib24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","article-title":"Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction","volume":"10","author":"Fulgenzi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.10.002_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus bevacizumab in patients with child\u2013Pugh B advanced hepatocellular carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.10.002_bib26","article-title":"Real-world outcomes of combination immunotherapy in patients with Child\u2013Pugh class B hepatocellular carcinoma","volume":"44","author":"Yamazaki","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.10.002_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?","volume":"8","author":"Abdelhamed","year":"2024","journal-title":"Liver Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826029193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826029193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:21:36Z","timestamp":1791933696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826029193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S0168827826029193"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.10.002","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}